Wörwag Research and Development GmbH is a subsidiary of Wörwag Pharma Group dedicated to developing generic, OTC, and new chemical entity products and medical devices according to European guidelines. Its business model involves licensing out its developed products in Europe and worldwide. The document provides readily compiled dossiers for several generic drug products that have received German and European marketing authorizations and are available for submission in other markets. It also outlines ongoing development projects and provides contact information.

1. WÖRWAG R&D GmbH - Company profile for products to licence
out
Wörwag Research and Development GmbH
A subsidiary of the Wörwag Pharma Group dedicated to the development of:
● Generic
● OTC
● NCE products and
● Medical devices
according to European guidelines
Mission
● Provide excellent products right in time for launch with maximum therapeutic
benefit for our patients
March 2011 I Wörwag R&D I Business Development www.woerwag-rd.com

2. WÖRWAG R&D GmbH - Company profile for products to licence
out
Wörwag Research and Development GmbH
Business model
● Licensing-out developments done by Wörwag R&D in Europe and Worldwide
on a national, European or worldwide basis.
Please find Wörwag R&D’s current development list and compiled / approved
dossiers on the following pages or on our homepage:
www.woerwag-rd.com
March 2011 I Wörwag R&D I Business Development www.woerwag-rd.com

3. WÖRWAG R&D GmbH - Company profile for products to licence out
(I)
Readily Compiled Dossiers (I):
Following dossiers are readily compiled and have received German and selected
European Marketing Authorisations. They are ready for submission in other
markets:
● Clopidogrel film coated tablets (75 mg); Original: Plavix, Iscover
● Candesartan tablets (2 | 4 | 8 | 16 | 32 mg), Original: Atacand
● Donepezil film coated tablets (5 | 10 mg), Original: Aricept
● Levetiracetam film coated tablets (250 | 500 | 750 | 1000 mg), Original:
Keppra
● Pioglitazon tablets (15 | 30 | 45 mg), Original: Actos of German origin
(Bulk and Packaging)
March 2011 I Wörwag R&D I Business Development www.woerwag-rd.com

4. WÖRWAG R&D GmbH - Company profile for products to licence out
(II)
Readily Compiled Dossiers (II):
● Valsartan tablets (40 | 80 | 160 | 320 mg), Original: Diovan of German
origin (Bulk and Packaging)
● Losartan film coated tablets (12,5 | 25 | 50 | 100 mg); Original: Lorzaar
● Losartan-HCT film coated tablets (50/12,5 | 100/12,5 | 100/25 mg);
Original: Lorzaar Plus
March 2011 I Wörwag R&D I Business Development www.woerwag-rd.com

5. WÖRWAG R&D GmbH - Company profile for products to licence out
(III)
Readily Compiled Dossiers (III):
● Torasemid tablets (2,5 | 5 | 10 | 20 | 200 mg); Original: Torem, Unat
● Xipamid tablets (10 | 20 | 40 mg); Original: Aquaphor
● Enalapril-HCT tablets (20/12,5 mg); Original: Benalapril Plus
● HCT tablets (12,5 | 25 mg); Original: Esidrix
● Milk Thistle Dry Extract, film coated tablets, corresponding to 150 mg
Silymarin (UV)
● Milk Thistle Dry Extract, capsules, corresponding to 86,5 mg Silymarin
(HPLC)
● Capsicum Cream (0,05 % Capsaicin), OTC product indicated for pain relief
due to chronic diabetic neuropathy
All products above are of German origin (Bulk and Packaging)
March 2011 I Wörwag R&D I Business Development www.woerwag-rd.com

6. WÖRWAG R&D GmbH - Company profile for products to licence out
(IV)
Ongoing developments
● Candesartan-HCT tablets (8/12,5 | 16/12,5 | 32/12,5 | 32/25 mg),
Dossier ready until Q III-2011, DCP in Q IV-2011; Original: Atacand Plus
● Galantamine XR capsules (8 | 16 | 24 mg), Dossier ready,
DCP ongoing; Original: Reminyl
● Duloxetin gastro-resistant capsules (30 | 60 mg),
Dossier ready in 2012, Data protection period until Aug. 2014; Original: Cymbalta
of German origin (Bulk and Packaging)
Please find more details on our homepage at:
www.woerwag-rd.com
March 2011 I Wörwag R&D I Business Development www.woerwag-rd.com

7. WÖRWAG R&D GmbH - Company profile for products to licence
out
Contact
Wörwag R & D GmbH
Calwer Str. 7
D-71034 Böblingen
Germany
Dr. Wolfgang Bäurle
Head Business Development
Tel.: +49 7031-6204-794
Fax: +49 7031-6204-72
E-mail: Wolfgang.Baeurle@woerwagpharma.com
Internet: www.woerwag-rd.com
March 2011 I Wörwag R&D I Business Development I Dr. Wolfgang Bäurle www.woerwag-rd.com